Modulation of eIF5A expression using SNS01 nanoparticles inhibits NF-κB activity and tumor growth in murine models of multiple myeloma

Molecular Therapy

Volumn 20, Issue 7, 2012, Pages 1305-1314

  Taylor, Catherine A ^a   Liu, Zhongda ^a   Tang, Terence C ^a   Zheng, Qifa ^a   Francis, Sarah ^a   Wang, Tzann Wei ^a   Ye, Bin ^a   Lust, John A ^b   Dondero, Richard ^c   Thompson, John E ^a,b  

^a UNIVERSITY OF WATERLOO   (Canada)

^b MAYO CLINIC   (United States)

^c Senesco Technologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPUSINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INITIATION FACTOR 5A; MITOGEN ACTIVATED PROTEIN KINASE; NANOPARTICLE; PLASMID VECTOR; POLYETHYLENEIMINE; SMALL INTERFERING RNA; SNS 01; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GENE THERAPY; CANCER INHIBITION; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; NANOPHARMACEUTICS; NONHUMAN; PROTEIN DEPLETION; PROTEIN PROCESSING; SYSTEMIC THERAPY; TUMOR XENOGRAFT;

EUKARYOTA; MURINAE;

EID: 84863496138     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.94     Document Type: Article

References (49)

1. Kang, HA and Hershey, JW (1994). Effect of initiation factor eIF-5A depletion on protein synthesis and proliferation of Saccharomyces cerevisiae. J Biol Chem 269: 3934-3940. (Pubitemid 24237736)
2. Zanelli, CF, Maragno, AL, Gregio, AP, Komili, S, Pandolfi, JR, Mestriner, CA et al. (2006). eIF5A binds to translational machinery components and affects translation in yeast. Biochem Biophys Res Commun 348: 1358-1366. (Pubitemid 44291350)
3. Gregio, AP, Cano, VP, Avaca, JS, Valentini, SR and Zanelli, CF (2009). eIF5A has a function in the elongation step of translation in yeast. Biochem Biophys Res Commun 380: 785-790.
4. Saini, P, Eyler, DE, Green, R and Dever, TE (2009). Hypusine-containing protein eIF5A promotes translation elongation. Nature 459: 118-121.
5. Liu, YP, Nemeroff, M, Yan, YP and Chen, KY (1997). Interaction of eukaryotic initiation factor 5A with the human immunodeficiency virus type 1 Rev response element RNA and U6 snRNA requires deoxyhypusine or hypusine modification. Biol Signals 6: 166-174. (Pubitemid 27380008)
6. Maier, B, Ogihara, T, Trace, AP, Tersey, SA, Robbins, RD, Chakrabarti, SK et al. (2010). The unique hypusine modification of eIF5A promotes islet beta cell inflammation and dysfunction in mice. J Clin Invest 120: 2156-2170.
7. Park, MH, Nishimura, K, Zanelli, CF and Valentini, SR (2010). Functional significance of eIF5A and its hypusine modification in eukaryotes. Amino Acids 38: 491-500.
8. Cracchiolo, BM, Heller, DS, Clement, PM, Wolff, EC, Park, MH and Hanauske-Abel, HM (2004). Eukaryotic initiation factor 5A-1 (eIF5A-1) as a diagnostic marker for aberrant proliferation in intraepithelial neoplasia of the vulva. Gynecol Oncol 94: 217-222. (Pubitemid 38950524)
9. Taylor, CA, Sun, Z, Cliche, DO, Ming, H, Eshaque, B, Jin, S et al. (2007). Eukaryotic translation initiation factor 5A induces apoptosis in colon cancer cells and associates with the nucleus in response to tumour necrosis factor alpha signalling. Exp Cell Res 313: 437-449. (Pubitemid 46186299)
10. Sun, Z, Cheng, Z, Taylor, CA, McConkey, BJ and Thompson, JE (2010). Apoptosis induction by eIF5A1 involves activation of the intrinsic mitochondrial pathway. J Cell Physiol 223: 798-809.
11. Li, AL, Li, HY, Jin, BF, Ye, QN, Zhou, T, Yu, XD et al. (2004). A novel eIF5A complex functions as a regulator of p53 and p53-dependent apoptosis. J Biol Chem 279: 49251-49258. (Pubitemid 39625810)
12. Caraglia, M, Park, MH, Wolff, EC, Marra, M and Abbruzzese, A (2011). eIF5A isoforms and cancer: two brothers for two functions? Amino Acids.
13. Moore, CC, Martin, EN, Lee, G, Taylor, C, Dondero, R, Reznikov, LL et al. (2008). Eukaryotic translation initiation factor 5A small interference RNA-liposome complexes reduce inflammation and increase survival in murine models of severe sepsis and acute lung injury. J Infect Dis 198: 1407-1414.
14. Jin, S, Taylor, CA, Liu, Z, Sun, Z, Ye, B and Thompson JE (2008). Suppression of primary and disseminated murine tumor growth with eIF5A1 gene therapy. Gene Ther Mol Biol 12: 207-218.
15. Ramaswamy, S, Ross, KN, Lander, ES and Golub, TR (2003). A molecular signature of metastasis in primary solid tumors. Nat Genet 33: 49-54. (Pubitemid 36068681)
16. Coller, HA, Grandori, C, Tamayo, P, Colbert, T, Lander, ES, Eisenman, RN et al. (2000). Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci USA 97: 3260-3265. (Pubitemid 30183289)
17. Balabanov, S, Gontarewicz, A, Ziegler, P, Hartmann, U, Kammer, W, Copland, M et al. (2007). Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood 109: 1701-1711. (Pubitemid 46239605)
18. Caraglia, M, Marra, M, Giuberti, G, D'Alessandro, AM, Baldi, A, Tassone, P et al. (2003). The eukaryotic initiation factor 5A is involved in the regulation of proliferation and apoptosis induced by interferon-alpha and EGF in human cancer cells. J Biochem 133: 757-765. (Pubitemid 36898647)
19. Caraglia, M, Vitale, G, Marra, M, Del Prete, S, Lentini, A, Budillon, A et al. (2004). Translational and post-translational modifications of proteins as a new mechanism of action of alpha-interferon: review article. Amino Acids 26: 409-417. (Pubitemid 39093144)
20. Schmitz, ML, Bacher, S and Kracht, M (2001). I kappa B-independent control of NFkappa B activity by modulatory phosphorylations. Trends Biochem Sci 26: 186-190. (Pubitemid 32197579)
21. Yang, F, Tang, E, Guan, K and Wang, CY (2003). IKK beta plays an essential role in the phosphorylation of RelA/p65 on serine 536 induced by lipopolysaccharide. J Immunol 170: 5630-5635. (Pubitemid 36617854)
22. Sasaki, CY, Barberi, TJ, Ghosh, P and Longo, DL (2005). Phosphorylation of RelA/p65 on serine 536 defines an I{kappa}B{alpha}-independent NF-{kappa}B pathway. J Biol Chem 280: 34538-34547. (Pubitemid 41504584)
23. Klier, H, Csonga, R, Joäo, HC, Eckerskorn, C, Auer, M, Lottspeich, F et al. (1995). Isolation and structural characterization of different isoforms of the hypusine-containing protein eIF-5A from HeLa cells. Biochemistry 34: 14693-14702.
24. Vanden Berghe, W, Plaisance, S, Boone, E, De Bosscher, K, Schmitz, ML, Fiers, W et al. (1998). p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor. J Biol Chem 273: 3285-3290. (Pubitemid 28109741)
25. Vermeulen, L, De Wilde, G, Van Damme, P, Vanden Berghe, W and Haegeman, G (2003). Transcriptional activation of the NF-kappaB p65 subunit by mitogen-and stress-activated protein kinase-1 (MSK1). EMBO J 22: 1313-1324. (Pubitemid 36362695)
26. Tan, X, Wang, DB, Lu, X, Wei, H, Zhu, R, Zhu, SS et al. (2010). Doxorubicin induces apoptosis in H9c2 cardiomyocytes: role of overexpressed eukaryotic translation initiation factor 5A. Biol Pharm Bull 33: 1666-1672.
27. Shi, XP, Yin, KC, Ahern, J, Davis, LJ, Stern, AM and Waxman, L (1996). Effects of N1-guanyl-1,7-diaminoheptane, an inhibitor of deoxyhypusine synthase, on the growth of tumorigenic cell lines in culture. Biochim Biophys Acta 1310: 119-126.
28. Jasiulionis, MG, Luchessi, AD, Moreira, AG, Souza, PP, Suenaga, AP, Correa, M et al. (2007). Inhibition of eukaryotic translation initiation factor 5A (eIF5A) hypusination impairs melanoma growth. Cell Biochem Funct 25: 109-114. (Pubitemid 46121789)
29. Lee, SB, Park, JH, Kaevel, J, Sramkova, M, Weigert, R and Park, MH (2009). The effect of hypusine modification on the intracellular localization of eIF5A. Biochem Biophys Res Commun 383: 497-502.
30. Ni, H, Ergin, M, Huang, Q, Qin, JZ, Amin, HM, Martinez, RL et al. (2001). Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. Br J Haematol 115: 279-286. (Pubitemid 34203489)
31. Oh, SM, Lee, SH, Lee, BJ, Pyo, CW, Yoo, NK, Lee, SY et al. (2007). A distinct role of neutrophil lactoferrin in RelA/p65 phosphorylation on Ser536 by recruiting TNF receptor-associated factors to IkappaB kinase signaling complex. J Immunol 179: 5686-5692.
32. Haller, D, Russo, MP, Sartor, RB and Jobin, C (2002). IKK beta and phosphatidylinositol 3-kinase/Akt participate in non-pathogenic Gram-negative enteric bacteria-induced RelA phosphorylation and NF-kappa B activation in both primary and intestinal epithelial cell lines. J Biol Chem 277: 38168-38178. (Pubitemid 35154670)
33. Doyle, SL, Jefferies, CA and O'Neill, LA (2005). Bruton's tyrosine kinase is involved in p65-mediated transactivation and phosphorylation of p65 on serine 536 during NFkappaB activation by lipopolysaccharide. J Biol Chem 280: 23496-23501. (Pubitemid 40884827)
34. O'Mahony, AM, Montano, M, Van Beneden, K, Chen, LF and Greene, WC (2004). Human T-cell lymphotropic virus type 1 tax induction of biologically Active NF-kappaB requires IkappaB kinase-1-mediated phosphorylation of RelA/p65. J Biol Chem 279: 18137-18145. (Pubitemid 38623226)
35. Jiang, X, Takahashi, N, Matsui, N, Tetsuka, T and Okamoto, T (2003). The NF-kappa B activation in lymphotoxin beta receptor signaling depends on the phosphorylation of p65 at serine 536. J Biol Chem 278: 919-926. (Pubitemid 36790766)
36. Bohuslav, J, Chen, LF, Kwon, H, Mu, Y and Greene, WC (2004). p53 induces NF-kappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J Biol Chem 279: 26115-26125. (Pubitemid 38798756)
37. Frydas, S, Papazahariadou, M, Papaioannou, N, Hatzistilianou, M, Trakatellis, M, Merlitti, D et al. (2003). Effect of the compound L-mimosine in an in vivo model of chronic granuloma formation induced by potassium permanganate (KMNO4). Int J Immunopathol Pharmacol 16: 99-104. (Pubitemid 36850848)
38. Templin, AT, Maier, B, Nishiki, Y, Tersey, SA and Mirmira, RG (2011). Deoxyhypusine synthase haploinsufficiency attenuates acute cytokine signaling. Cell Cycle 10: 1043-1049.
39. Sun, Y and Oberley, LW (1996). Redox regulation of transcriptional activators. Free Radic Biol Med 21: 335-348. (Pubitemid 26271723)
40. Hu, J, Nakano, H, Sakurai, H and Colburn, NH (2004). Insufficient p65 phosphorylation at S536 specifically contributes to the lack of NF-kappaB activation and transformation in resistant JB6 cells. Carcinogenesis 25: 1991-2003. (Pubitemid 39405920)
41. Piazza, FA, Gurrieri, C, Trentin, L and Semenzato, G (2007). Towards a new age in the treatment of multiple myeloma. Ann Hematol 86: 159-172. (Pubitemid 46195988)
42. Hermanson, GG, Eisenberg, D, Kincade, PW and Wall, R (1988). B29: a member of the immunoglobulin gene superfamily exclusively expressed on beta-lineage cells. Proc Natl Acad Sci USA 85: 6890-6894.
43. Thompson, AA, Wood, WJ Jr, Gilly, MJ, Damore, MA, Omori, SA and Wall, R (1996). The promoter and 5' flanking sequences controlling human B29 gene expression. Blood 87: 666-673.
44. Malone, CS, Kuraishy, AI, Fike, FM, Loya, RG, Mikkili, MR, Teitell, MA et al. (2006). B29 gene silencing in pituitary cells is regulated by its 3' enhancer. J Mol Biol 362: 173-183. (Pubitemid 44278857)
45. Reyes-Sandoval, A and Ertl, HC (2004). CpG methylation of a plasmid vector results in extended transgene product expression by circumventing induction of immune responses. Mol Ther 9: 249-261. (Pubitemid 38256551)
46. Yew, NS, Zhao, H, Przybylska, M, Wu, IH, Tousignant, JD, Scheule, RK et al. (2002). CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo. Mol Ther 5: 731-738. (Pubitemid 34619066)
47. Bonnet, ME, Erbacher, P and Bolcato-Bellemin, AL (2008). Systemic delivery of DNA or siRNA mediated by linear polyethylenimine (L-PEI) does not induce an inflammatory response. Pharm Res 25: 2972-2982.
48. Lisziewicz, J, Trocio, J, Whitman, L, Varga, G, Xu, J, Bakare, N et al. (2005). DermaVir: a novel topical vaccine for HIV/AIDS. J Invest Dermatol 124: 160-169. (Pubitemid 40100965)
49. Liu, H, Liu, L, Fletcher, BS and Visner, GA (2006). Sleeping Beauty-based gene therapy with indoleamine 2,3-dioxygenase inhibits lung allograft fibrosis. FASEB J 20: 2384-2386.